Atossa Therapeutics Inc ATOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATOS is a good fit for your portfolio.
News
-
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
-
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
-
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
-
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
-
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
-
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
-
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $1.61
- Day Range
- $1.55–1.66
- 52-Week Range
- $0.63–2.30
- Bid/Ask
- $1.65 / $1.66
- Market Cap
- $207.50 Mil
- Volume/Avg
- 584,936 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.76%
Company Profile
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
Comparables
Valuation
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.36 | 0.88 | 0.60 |
Price/Sales | — | 30.84 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ATOS
VIR
AVIR
Financial Strength
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Quick Ratio | 15.76 | 12.22 | 17.86 |
Current Ratio | 16.34 | 12.90 | 18.24 |
Interest Coverage | — | — | — |
Quick Ratio
ATOS
VIR
AVIR
Profitability
Metric
|
ATOS
|
VIR
|
AVIR
|
---|---|---|---|
Return on Assets (Normalized) | −22.62% | −19.57% | −15.46% |
Return on Equity (Normalized) | −23.64% | −24.29% | −16.16% |
Return on Invested Capital (Normalized) | −28.25% | −27.25% | −19.92% |
Return on Assets
ATOS
VIR
AVIR
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tlgkcsnmw | Lxvz | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bwwngzmj | Ljzvcp | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vbmsnhzg | Ztcwbh | $107.8 Bil | |
MRNA
| Moderna Inc | Zsxsdybjn | Lthz | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Wdpknhnz | Jmft | $22.2 Bil | |
ARGX
| argenx SE ADR | Wygpqyrs | Hpnt | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgjrplgjz | Wpbgjwh | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nyyxkclq | Dqfmxm | $15.1 Bil | |
INCY
| Incyte Corp | Qsdpwcgpx | Tlpdgd | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vlgqdkrgb | Rtvxf | $12.7 Bil |